Met, metastasis, motility and more

Nature Reviews Molecular Cell Biology

Volumn 4, Issue 12, 2003, Pages 915-925

  Birchmeier, Carmen ^a   Birchmeier, Walter ^a   Gherardi, Ermanno ^b   Vande Woude, George F ^c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2 ASSOCIATED BINDER 1; MUTANT PROTEIN; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TYROSINE KINASE MET; UNCLASSIFIED DRUG;

CAENORHABDITIS ELEGANS; CANCER CELL; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; DOWNSTREAM PROCESSING; DROSOPHILA MELANOGASTER; EMBRYO DEVELOPMENT; HUMAN; METASTASIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; VERTEBRATE;

ANIMALS; BINDING SITES; CELL LINE; CELL MOVEMENT; CELL SIZE; HEPATOCYTE GROWTH FACTOR; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, MOLECULAR; MORPHOGENESIS; NEOPLASM METASTASIS; NEOPLASMS; PHOSPHOPROTEINS; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

CAENORHABDITIS; CAENORHABDITIS ELEGANS; DROSOPHILA MELANOGASTER; MELANOGASTER; VERTEBRATA;

EID: 0345601083     PISSN: 14710072     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrm1261     Document Type: Review

References (109)

1. Cooper, C. S. et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311, 29-33 (1984).
2. Park, M. et al. Mechanism of met oncogene activation. Cell 45, 895-904 (1986). Early molecular characterization of the Tpr-Met oncogene and the Met proto-oncogene.
3. Stoker, M., Gherardi, E., Perryman, M. & Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327, 239-242 (1987). Reports the characterization of a fibroblast-derived protein which causes 'scattering' of epithelial cells (scatter factor). The report describes the isolation of the factor from fibroblasts and establishes its paracrine mechanism of action.
4. Nakamura, T. et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440-443 (1989).
5. Miyazawa, K. et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem. Biophys. Res. Commun. 163, 967-973 (1989).
6. Zarnegar, R. & Michalopoulos, G. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res. 49, 3314-3320 (1989). References 4-6 report the purification of hepatocyte growth factor (HGF) and the cloning and sequencing of HGF cDNA. These papers established that the two chains of HGF are encoded by a single transcript and that HGF contains kringle domains and an inactive serine proteinase domain.
7. Weidner, K. M. et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl Acad. Sci. USA 88, 7001-7005 (1991).
8. Gherardi, E. & Stoker, M. Hepatocytes and scatter factor. Nature 346, 228 (1990).
9. Bottaro, D. P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802-804 (1991).
10. Donate, L. E. et al. Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci. 3, 2378-2394 (1994).
11. Gherardi, E. et al. Functional map and domain structure of the MET (HGF/SF) receptor. Proc. Natl Acad. Sci. USA 100, 12039-12044 (2003). A mutagenesis study of the extracellular part of Met that maps HGF/SF binding to the sema domain. The study also provides three-dimensional models of the sema and Ig domains of Met.
12. Ponzetto, C. et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77, 261-271 (1994). The bidentate docking site in the carboxy-terminal domain of Met is identified. Phosphorylation of this site allows interactions with multiple SH2-domain-containing signal transducers, and its mutation results in loss of signalling function of Met.
13. Weidner, K. M. et al. Interaction between gab1 and the c met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384, 173-176 (1996).
14. Sachs, M. et al. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J. Cell Biol. 150, 1375-1384 (2000). A study of the genetic analysis of Gab1 by targeted mutagenesis in mice. Remarkably similar phenotypes of the Gab1 and Met mutations are reported, which shows the essential role of Gab1 in Met signalling.
15. Montesano, R., Matsumoto, K., Nakamura, T. & Orci, L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67, 901-908 (1991).
16. Schmidt, C. et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373, 699-702 (1995).
17. Uehara, Y. et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373, 702-705 (1995).
18. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A. & Birchmeier, C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768-771 (1995). Limb muscles develop from cells that migrate from the somites. The authors report here that in Met-homozygous-mutant-mouse embryos, myogenic precursor cells do not invade the limb buds and, as a consequence, skeletal muscles of the limbs do not form. By contrast, development of the paraxial skeletal muscles proceeds in the absence of Met.
19. Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet. 16, 68-73 (1997). Hereditary papillary renal carcinoma is a form of kidney cancer that is characterized by a predisposition to develop multiple, renal tumours. Here, the first missense mutations in Met in hereditary tumours - papillary renal carcinomas - and in sporadic forms of renal cancer are identified.
20. Lokker, N. A. et al. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. 11, 2503-2510 (1992).
21. Schwall, R. H. et al. Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2. J. Cell Biol. 133, 709-718 (1996).
22. Hartmann, G. et al. Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. Curr. Biol. 8, 125-134 (1998).
23. DiGabriele, A. D. et al. Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature 393, 812-817 (1998).
24. Ultsch, M., Lokker, N. A., Godowski, P. J. & de Vos, A. M. Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution. Structure 6, 1383-1393 (1998).
25. Chirgadze, D. Y. et al. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nature Struct. Biol. 6, 72-79 (1999).
26. Lietha, D., Chirgadze, D. Y., Mulloy, B., Blundell, T. L. & Gherardi, E. Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J. 20, 5543-5555 (2001). A crystallographic analysis of the NK1 fragment of HGF/SF in complex with heparin. The study defines the heparin-binding site in the amino-terminal domain and provides the basis for engineering NK1 variants with full agonistic activity.
27. Lokker, N. A., Presta, L. G. & Godowski, P. J. Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-Met receptor. Protein Eng. 7, 895-903 (1994).
28. 3 in complex with an Arg-Gly-Asp ligand. Science 296, 151-155 (2002).
29. Leonard, E. J. & Danilkovitch, A. Macrophage stimulating protein. Adv. Cancer. Res. 77, 139-167 (2000).
30. Raabe, T. et al. DOS, a novel pleckstrin homology domain-containing protein required for signal transduction between sevenless and Ras1 in Drosophila. Cell 85, 911-920 (1996).
31. Schutzman, J. L. et al. The Caenorhabditis elegans EGL-15 signaling pathway implicates a DOS-like multisubstrate adaptor protein in fibroblast growth factor signal transduction. Mol. Cell. Biol. 21, 8104-8116 (2001). References 30 and 31 report the identification of the Drosophila and C. elegans Gab homologues, Dos and Soc1, and show the requirement for these genes in the signalling of receptor tyrosine kinases.
32. Lock, L. S., Royal, I., Naujokas, M. A. & Park, M. Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and-independent recruitment of Gab1 to receptor tyrosine kinases. J. Biol. Chem. 275, 31536-31545 (2000).
33. Stefan, M. et al. Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis. J. Biol. Chem. 276, 3017-3023 (2001).
34. Sachs, M. et al. Motogenic and morphogenic activity of epithelial receptor tyrosine kinases. J. Cell Biol. 133, 1095-1107 (1996).
35. Maroun, C. R. et al. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 19, 1784-1799 (1999).
36. Schaeper, U. et al. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J. Cell Biol. 149, 1419-1432 (2000).
37. Gu, H. & Neel, B. G. The 'Gab' in signal transduction. Trends Cell Biol. 13, 122-130 (2003).
38. Rosario, M. & Birchmeier, W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol. 13, 328-335 (2003).
39. Cunnick, J. M. et al. Regulation of the mitogen-activated protein kinase signaling pathway by SHP2. J. Biol. Chem. 277, 9498-9504 (2002).
40. Jeffers, M., Taylor, G. A., Weidner, K. M., Omura, S. & Vande Woude, G. F. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol. Cell. Biol. 17, 799-808 (1997).
41. Peschard, P. et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995-1004 (2001). The authors show that Cbl promotes ubiquitylation of Met. Cbl binds to the active Met receptor at a docking site in the juxtamembrane domain of Met. This docking site is absent in the Trp-Met oncogene.
42. Hammond, D. E., Urbe, S., Vande Woude, G. F. & Clague, M. J. Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 20, 2761-2770 (2001).
43. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nature Rev. Cancer 2, 442-454 (2002).
44. Weidner, K. M., Behrens, J., Vandekerckhove, J. & Birchmeier, W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J. Cell Biol. 111, 2097-2108 (1990).
45. Potempa, S. & Ridley, A. J. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell 9, 2185-2200 (1998).
46. Hartmann, G., Weidner, K. M., Schwarz, H. & Birchmeier, W. The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. J. Biol. Chem. 269, 21936-21939 (1994).
47. Ridley, A. J., Comoglio, P. M. & Hall, A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol. Cell. Biol. 15, 1110-1122 (1995). An analysis of the roles of Ras, Rac and Rho in regulating responses to HGF/SF by microinjection of dominant inhibitory proteins. The authors report that inhibition of endogenous Ras proteins prevents HGF/SF-induced actin reorganization, spreading and scattering, and a dominant inhibitor of Rac prevents HGF/SF-induced spreading and actin reorganization.
48. Khwaja, A., Lehmann, K., Marte, B. M. & Downward, J. Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J. Biol. Chem. 273, 18793-18801 (1998).
49. Paumelle, R. et al. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene 21, 2309-2319 (2002).
50. Royal, I., Lamarche-Vane, N., Lamorte, L., Kaibuchi, K. & Park, M. Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Mol. Biol. Cell 11, 1709-1725 (2000).
51. Sakkab, D. et al. Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL. J. Biol. Chem. 275, 10772-10778 (2000).
52. Lamorte, L., Kamikura, D. M. & Park, M. A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein. Oncogene 19, 5973-5981 (2000).
53. Fan, S. et al. The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol. Cell Biol. 21, 4968-4984 (2001).
54. Xiao, G. H. et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl Acad. Sci. USA 98, 247-252 (2001).
55. Garcia-Guzman, M., Dolfi, F., Zeh, K. & Vuori, K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1-Crk signaling complex formation. Oncogene 18, 7775-7786 (1999).
56. Boccaccio, C. et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391, 285-288 (1998).
57. Zhang, Y. W., Wang, L. M., Jove, R. & Vande Woude, G. F. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21, 217-226 (2002).
58. Schaper, F. et al. Hepatocyte growth factor/scatter factor (HGF/SF) signals via the STAT3/APRF transcription factor in human hepatoma cells and hepatocytes. FEBS Lett. 405, 99-103 (1997).
59. Müller, M., Morotti, A. & Ponzetto, C. Activation of NF-κB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol. Cell. Biol. 22, 1060-1072 (2002).
60. Monga, S. P. et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes. Cancer Res. 62, 2064-2071 (2002).
61. Muller, T., Bain, G., Wang, X. & Papkoff, J. Regulation of epithelial cell migration and tumor formation by β-catenin signaling. Exp. Cell Res. 280, 119-133 (2002).
62. Orian-Rousseau, V., Chen, L., Sleeman, J. P., Herrlich, P. & Ponta, H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16, 3074-3086 (2002).
63. Giordano, S. et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nature Cell Biol. 4, 720-724 (2002).
64. Wang, X. et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol. Cell 9, 411-421 (2002).
65. 4 integrin in the control of HGF-dependent invasive growth. Cell 107, 643-654 (2001).
66. Crepaldi, T., Gautreau, A., Comoglio, P. M., Louvard, D. & Arpin, M. Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J. Cell Biol. 138, 423-434 (1997).
67. Schmits, R. et al. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 90, 2217-2233 (1997).
68. 4 integrin is required for hemidesmosome formation, cell adhesion and cell survival. J. Cell Biol. 134, 559-572 (1996).
69. Neyt, C. et al. Evolutionary origins of vertebrate appendicular muscle. Nature 408, 82-86 (2000).
70. Itoh, M. et al. Role of Gab1 in heart, placenta, and skin development and growth factor- and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation. Mol. Cell. Biol. 20, 3695-3704 (2000).
71. Ieraci, A., Forni, P. E. & Ponzetto, C. Viable hypomorphic signaling mutant of the Met receptor reveals a role for hepatocyte growth factor in postnatal cerebellar development. Proc. Natl Acad. Sci. USA 99, 15200-15205 (2002).
72. Maina, F. & Klein, R. Hepatocyte growth factor, a versatile signal for developing neurons. Nature Neurosci. 2, 213-217 (1999).
73. Dietrich, S. et al. The role of SF/HGF and c-Met in the development of skeletal muscle. Development 126, 1621-1629 (1999).
74. Michalopoulos, G. K. & DeFrances, M. C. Liver regeneration. Science 276, 60-66 (1997).
75. Nakamura, T., Mizuno, S., Matsumoto, K., Sawa, Y. & Matsuda, H. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 106, 1511-1519 (2000).
76. Matsumoto, K. & Nakamura, T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int. 59, 2023-2038 (2001).
77. Rabkin, R. et al. Hepatocyte growth factor receptor in acute tubular necrosis. J. Am. Soc. Nephrol. 12, 531-540 (2001).
78. Jin, H. et al. Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction. J. Pharmacol. Exp. Ther. 304, 654-660 (2003).
79. Roos, F., Ryan, A. M., Chamow, S. M., Bennett, G. L. & Schwall, R. H. Induction of liver growth in normal mice by infusion of hepatocyte growth factor/scatter factor. Am. J. Physiol. 268, G380-G386 (1995).
80. Rosen, E. M. & Goldberg, I. D. Regulation of angiogenesis by scatter factor. EXS 79, 193-208 (1997).
81. Rong, S., Segal, S., Anver, M., Resau, J. H. & Vande Woude, G. F. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl Acad. Sci. USA 91, 4731-4735 (1994). The authors show that NIH-3T3 cells that co-express Met and HGF/SF metastasize in an animal model.
82. Abounader, R. et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 16, 108-110 (2002).
83. Takayama, H. et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl Acad. Sci. USA 94, 701-706 (1997).
84. Danilkovitch-Miagkova, A. & Zbar, B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 109, 863-867 (2002).
85. Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J. & Bishop, J. M. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153, 1023-1034 (2001).
86. Furge, K. A. et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc. Natl Acad. Sci. USA 98, 10722-10727 (2001).
87. Ivan, M., Bond, J. A., Prat, M., Comoglio, P. M. & Wynford-Thomas, D. Activated ras and rel oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14, 2417-2423 (1997).
88. Kitamura, S. et al. Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Br. J. Cancer 83, 668-673 (2000).
89. Derksen, P. W. et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17, 764-774 (2003).
90. Xin, X. et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am. J. Pathol. 158, 1111-1120 (2001).
91. Morotti, A., Mila, S., Accornero, P., Tagliabue, E. & Ponzetto, C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21, 4885-4893 (2002).
92. Atabey, N. et al. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J. Biol. Chem. 276, 14308-14314 (2001).
93. Webb, C. P. et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 60, 342-349 (2000).
94. Schwall, R. & Tabor, K. H. Hepatocyte growth factor receptor antagonists and uses thereof. US Patent 6,468,529 (2002).
95. Cao, B. et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl Acad. Sci. USA 98, 7443-7448 (2001).
96. Maehara, N. et al. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br. J. Cancer 84, 864-873 (2001).
97. Longati, P., Comoglio, P. M. & Bardelli, A. Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. Curr. Drug Targets 2, 41-55 (2001).
98. Shawver, L. K., Slamon, D. & Ullrich, A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1, 117-123 (2002).
99. Laird, A. D. & Cherrington, J. M. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin. Investig. Drugs 12, 51-64 (2003).
100. Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31-36 (2002).
101. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
102. Pollack, A. L., Runyan, R. B. & Mostov, K. E. Morphogenetic mechanisms of epithelial tubulogenesis: MDCK cell polarity is transiently rearranged without loss of cell-cell contact during scatter factor/hepatocyte growth factor-induced tubulogenesis. Dev. Biol. 204, 64-79 (1998).
103. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
104. Hay, R. et al. Radioimmunoscintigraphy of tumors autocrine for human Met and hepatocyte growth factor/scatter factor. Mol. Imaging 1, 56-62 (2002).
105. Shaharabany, M. et al. In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors. Cancer Res. 61, 4873-4878 (2001).
106. Jeffers, M. et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl Acad. Sci. USA 94, 11445-11450 (1997).
107. Hubbard, S. R., Wei, L., Ellis, L. & Hendrickson, W. A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746-754 (1994).
108. Miller, M. et al. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins 44, 32-43 (2001).
109. Birchmeier, C. & Brohmann, H. Genes that control the development of migrating muscle precursor cells. Curr. Opin. Cell Biol. 12, 725-730 (2000).